Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of anamorelin for cancer-associated weight loss and anorexia in advanced NSCLC
2018-002926-22Phase 3Completed
- Sponsor
- Helsinn
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) and anorexia nervosa (AN) comparing Anamorelin with Placebo (2 arms). Primary endpoint: Composite Clinical Response at Week 9. Started Feb 2019; status: completed.
02
Drugs
anamorelin
03
Conditions
cancer anorexia-cachexia syndrome (CACS)anorexia nervosa (AN)
Beyond the preview
Go deeper on 2018-002926-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002926-22.